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Abstract: The adrenal medulla is composed predominantly of chromaffin cells producing and secreting
the catecholamines dopamine, norepinephrine, and epinephrine. Catecholamine biosynthesis and
secretion is a complex and tightly controlled physiologic process. The pathways involved have
been extensively studied, and various elements of the underlying molecular machinery have been
identified. In this review, we provide a detailed description of the route from stimulus to secretion
of catecholamines by the normal adrenal chromaffin cell compared to chromaffin tumor cells in
pheochromocytomas. Pheochromocytomas are adrenomedullary tumors that are characterized by
uncontrolled synthesis and secretion of catecholamines. This uncontrolled secretion can be partly
explained by perturbations of the molecular catecholamine secretory machinery in pheochromocytoma
cells. Chromaffin cell tumors also include sympathetic paragangliomas originating in sympathetic
ganglia. Pheochromocytomas and paragangliomas are usually locally confined tumors, but about
15% do metastasize to distant locations. Histopathological examination currently poorly predicts
future biologic behavior, thus long term postoperative follow-up is required. Therefore, there is an
unmet need for prognostic biomarkers. Clearer understanding of the cellular mechanisms involved
in the secretory characteristics of pheochromocytomas and sympathetic paragangliomas may offer
one approach for the discovery of novel prognostic biomarkers for improved therapeutic targeting
and monitoring of treatment or disease progression.
Keywords: PPGL; catecholamines; adrenomedullary function
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1. Introduction
The adrenal medulla occupies the central portion of the adrenal gland and accounts for about 10%
of total adrenal gland volume [1]. The adrenal medulla is essentially a specialized sympathetic ganglion
releasing hormones in response to neural input and therefore is an integral part of the autonomic nervous
system [2,3]. The adrenomedullary chromaffin cells are embryologically derived from migrating neural
crest cells that develop into sympathoadrenal progenitors [4,5]. These sympathoadrenal progenitor
cells also give rise to the chromaffin cells present in the sympathetic chain and prevertebral paraganglia.
During adrenal organogenesis, close interactions between its two components, medulla and cortex, are
necessary for differentiation, morphogenesis, and survival of the adrenal gland. This cortical–chromaffin
crosstalk remains important for physiological regulation of adrenal hormone biosynthesis in adult
life and also is relevant for the pathogenesis of various adrenal gland disorders [6–9]. One of the
histological infrastructural requirements for this crosstalk is the centripetally directed arterial blood
flow from adrenal cortex to medulla. In addition, cortical cells are diffusely present in the adrenal
medulla and, conversely, chromaffin cells are intermixed with cortical cells within all three zones of the
adrenal cortex [10].
The principal function of the adrenal medulla is the biosynthesis and the secretion into the
circulation of the catecholamine epinephrine [6,11]. Epinephrine has a crucial role in the “fight-or-flight”
response, which allows an organism to adapt to stressful conditions. The acute rise in epinephrine in
response to physical or psychological stress stimuli results in hemodynamic and metabolic effects that
modulate various functions such as blood pressure, cardiac output, and blood glucose by acting on
cells expressing α- and β- adrenergic receptors [12,13]. Under basal conditions, however, epinephrine
functions as a circulating metabolic hormone, and it is the norepinephrine secreted by sympathetic
nerves acting immediately in the vicinity of exocytotic secretion that is the catecholamine mainly
regulating cardiovascular function. The norepinephrine that escapes re-uptake processes to enter the
circulation has negligible impact on the cardiovascular system. Nevertheless, both norepinephrine and
epinephrine secreted by pheochromocytomas in excessive amounts directly into the circulation can
have profound effects on cardiovascular function, with further impacts of co-secreted peptides. From a
clinical perspective, these tumors are the most important disease of the adrenal medulla. Chromaffin
cell tumors may also arise in extra-adrenal sympathetic paraganglia, in which case they are termed
sympathetic paragangliomas [14–16].
A cardinal feature of chromaffin cell tumors is their capacity to produce and secrete excessive
amounts of catecholamines, which may evoke signs and symptoms such as paroxysmal hypertension,
sweating, and tachycardia. The hypersecretion of catecholamines may cause acute, life-threatening
blood pressure elevations and arrhythmias and is associated with a significantly increased rate of
cardiovascular morbidity and mortality [17–20].
Pheochromocytomas and sympathetic paragangliomas are rare neuroendocrine tumors with
respective reported annual incidences of 0.46 and 0.11 per 100,000 individuals [21]. Detected incidence
of pheochromocytomas has doubled during the past two decades, most likely a result of changes
in diagnostic practices leading to earlier detection. The cornerstone of biochemical diagnosis of a
pheochromocytoma or a sympathetic paraganglioma is the demonstration of elevated plasma or urinary
concentrations of metanephrine, normetanephrine, or 3-methoxytyramine, i.e., the O-methylated
metabolites of epinephrine, norepinephrine, or dopamine, respectively [22]. Several anatomical and
functional imaging studies are available for localization of the tumor, after which curative treatment by
surgical resection can be offered [23].
Pheochromocytomas and paragangliomas are highly heterogeneous neuro-endocrine tumors
with regards to possible anatomic location, genetic context, symptomatology, metastatic potential,
and the degree of catecholamine release. Genetic mutations play a critical role in tumorigenesis and
affect various metabolic pathways, which also result in different mutation-dependent biochemical
phenotypes [3,24–26].
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In recent years, our knowledge of the genotype–phenotype interrelationship and metabolomics
of these intriguing neuro-endocrine tumors has expanded rapidly. Nevertheless, there are still
several areas of uncertainty. For instance, in the absence of metastases, it is difficult to predict
whether a pheochromocytoma or a paraganglioma will demonstrate a benign or a malignant clinical
course [16]. There are no clear-cut pathological markers to establish malignancy with certainty at
first presentation. Also, there is no straightforward relationship between the biochemical phenotype
of a pheochromocytoma or sympathetic paraganglioma and the associated signs or symptoms [3].
In the present review, we aim to provide a detailed picture of the pathways involved in catecholamine
production and secretion in normal adrenomedullary chromaffin cells. We also visit what is known
about the molecular perturbations in catecholamine biosynthesis and secretion in pheochromocytoma
and sympathetic paraganglioma. Improved understanding of these mechanisms at the molecular level
might provide insight into associated pathological complications, clarify highly variable presentations,
and aid in identification of new diagnostic or therapeutic strategies for personalized care.
2. Adrenomedullary Function
2.1. Biosynthesis of Catecholamines
Adrenomedullary catecholamine biosynthesis starts with uptake of the nonessential amino acid
L-tyrosine by the chromaffin cell. L-tyrosine is obtained from food sources or is derived from the
essential amino acid phenylalanine through the activity of phenylalanine hydroxylase, which is mainly
expressed in liver, kidney, and pancreas [27,28]. L-tyrosine is transported into the cytoplasm of the
adrenal chromaffin cell by the membrane bound L-type amino acid transporter system (LAT1 and
LAT2) [29,30]. Catecholamine biosynthesis involves the sequential activity of four enzymes: tyrosine
hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), dopamine β-hydroxylase (DBH),
and phenylethanolamine-N-methyltransferase (PNMT). Except for DBH, all these enzymes are localized
in the cytoplasm of the chromaffin cell (Figure 1). The end products of this biosynthetic route are
dopamine, norepinephrine, or epinephrine, depending on intracellular enzyme expression. Epinephrine
is mainly produced by the adrenomedullary chromaffin cells (>95%) and functions as a hormone
released directly into the bloodstream. In contrast, circulating norepinephrine is mainly derived from
overflow of the neurotransmitter from sympathetic nerve endings with adrenomedullary chromaffin
cell production providing usually a less than 10% contribution [11,13,31].
2.1.1. Tyrosine Hydroxylase
The initial and rate limiting step in catecholamine biosynthesis is the conversion of L-tyrosine to
L-3,4-dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase (TH, EC 1.14.16.2, molecular mass
of approximately 240 kDa) [32,33]. Locations of catecholamine biosynthesis are therefore dependent
on the expression of TH, which is largely confined to postganglionic sympathetic nerve endings
and adrenal and extra-adrenal chromaffin cells. In the adrenal medulla, this enzyme has a Km of
2 × 10−5 mol/L [27]. For this specific hydroxylation step, TH requires tetrahydrobiopterin, molecular
oxygen, and Fe2+ as cofactors. Tetrahydrobiopterin is synthesized from guanosine triphosphate
(GTP) and serves as a donor for hydrogen atoms to maintain TH in a reduced and active state [27,34].
The human TH gene is located at chromosome 11p15.5 and contains 13 exons [35], with four isoforms
produced by alternative mRNA splicing.
Regulation of TH activity is an important way to control catecholamine biosynthesis. This is
a complex process encompassing multiple modes of regulation. Short-term post-transcriptional
mechanisms include feedback inhibition by catecholamines, enzyme phosphorylation and
dephosphorylation, as well as ubiquitination. Long-term regulation mainly involves transcriptional
mechanisms [36]. The ubiquitin–proteasome pathway is thought to be involved in the degradation of
TH [37]. Catecholamines exert negative feedback control through oxidation of tetrahydrobiopterin
to pteridine, thereby preventing the formation of TH in its reduced active state [27]. In addition,
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catecholamines act as competitive antagonists of tetrahydrobiopterin at the active site of the catalytic
domain of TH [27]. Short-term regulation of TH activity is also achieved by a mechanism of
phosphorylation and dephosphorylation of one or more of the four serine residues at the regulatory
site of TH. Phosphorylation is catalyzed by multiple kinases (e.g., PKA, PKC, CaMKII, MAPKAP-K2,
ERK1, ERK2, MSK1, PRAK) and results in release from the feedback inhibition by catecholamines,
thereby stimulating enzyme activity.
Figure 1. The catecholamine biosynthetic pathway in an adrenomedullary chromaffin cell or a
pheochromocytoma cell. Norepinephrine and epinephrine are stored in separate chromaffin storage
vesicles. Abbreviations: LAT: L-type amino acid transporter; TH: tyrosine hydroxylase; L-DOPA:
L-3,4-dihydroxyphenylalanine; AADC: aromatic L-amino acid decarboxylase; DBH: dopamine
β-hydroxylase; PNMT: phenylethanolamine-N-methyltransferase; BH4: tetrahydrobiopterin; 02: molecular
oxygen; VitB6: pyridoxalphosphate; VitC: ascorbate; VMAT: vesicular monoamine transporters;
GR: glucocorticoid receptor.
Dephosphorylation by phosphatase PP2A, and to a lesser extent by PP2C, restores
catecholaminergic inhibition of the TH enzyme [36]. This negative feedback is mediated via
alpha2-adrenergic or D2-dopaminergic receptors, which activate cyclic adenosine monophosphate
(cAMP) or Ca2+/calmodulin-dependent protein phosphatases [27]. Prolonged stimulation of
catecholamine biosynthesis results in induction of TH protein synthesis through several cAMP
dependent pathways activating TH gene transcription [27,34,36,38–40].
Given the importance of its activity to catecholamine synthesis and the complexity of its regulation,
TH has gained great interest in many fields of biomedical research. Recent studies, for example,
have demonstrated the presence of several TH polymorphisms in the general population, some of
which appear associated with increased norepinephrine levels and elevated blood pressure [35,41].
2.1.2. Aromatic L-Amino Acid Decarboxylase
The next step in catecholamine biosynthesis is the decarboxylation of L-DOPA to dopamine
by cytosolic aromatic L-amino acid decarboxylase (AADC; EC 4.1.1.28). For this conversion,
pyridoxalphosphate (vitamin B6) is required as a cofactor [27,42]. AADC is a 100 kDa homodimeric
protein encoded by a single gene located at chromosome 7p12.1 with a Km of 4 × 10−4 mol/L [42,43].
The calculated Km greatly exceeds the endogenous concentration of L-DOPA, which means that
Cancers 2019, 11, 1121 5 of 33
the AADC enzyme is not fully saturated, and the rate at which dopamine can be synthesized is
therefore limited by the availability of L-DOPA as a substrate [42]. The AADC enzyme has a wide
tissue distribution and is not specific for chromaffin cells [42,44].
Short-term regulation of AADC enzyme activity by a previously postulated mechanism involving
cAMP or phosphorylation by protein kinases seems to play no significant role in the regulation of the
catecholamine biosynthetic pathway in situ [42,45]. The added value of AADC enzyme upregulation
by modulation of gene expression for physiological demands to increase catecholamine production in
postganglionic sympathetic nerve endings remains questionable [45–47].
2.1.3. Dopamine β-hydroxylase
In adrenal chromaffin cells, dopamine is further catalyzed to norepinephrine by dopamine
β-hydroxylase (DBH; EC 1.14.17.1). Because of the intravesicular location of DBH, dopamine first must
be translocated into norepinephrine storage vesicles by vesicular monoamine transporters (VMATs) [11].
The intravesicular conversion of dopamine represents the final step in the biosynthesis of norepinephrine.
DBH, a mixed-function oxidase, is a 290 kDa copper protein with a Km of 8.4 × 10−4 mol/L and utilizes
molecular oxygen, fumarate, and L-ascorbic acid as its main cofactors [27,48,49]. These requirements
for L-ascorbic acid and fumarate are not specific. Catechol (i.e., pyrocatechol or 1,2 dihydroxybenzene)
seems to be a weak substitute for L-ascorbic acid and other activating anions, such as acetate and
chloride, which can replicate the effects of fumarate at least partially [27,48,50–52].
In humans, DBH is encoded by a gene located at chromosome 9q34.2. Increased catecholamine
biosynthesis in response to stress is associated with increased levels of mRNAs encoding catecholamine
synthesizing enzymes. In adrenomedullary chromaffin cells, this response to stress is rapid, especially
for TH and PNMT [39]. Previous studies also revealed upregulation of adrenal DBH gene expression by
various transcriptional mechanisms in response to prolonged or repeated stressors [39,53]. However,
in contrast to TH, short or intermediate duration of stress does not result in a significant increase of
DBH mRNA [39].
2.1.4. Phenylethanolamine-N-Methyltransferase
Norepinephrine formed in the chromaffin vesicles diffuses passively into the cytosol,
where it is converted to epinephrine by the enzyme phenylethanolamine-N-methyl transferase
(PNMT; EC 2.1.1.28) [11,24]. PNMT, which has a predicted molecular weight of 30.9 kDa and a Km
of 9.2 × 10−6 mol/L, requires S-adenosylmethionine as a methyl donor and cosubstrate [27,54,55].
PNMT is not substrate specific and also is involved in the biosynthesis of other N-methylated trace
amines [11,27]. Expression of PNMT is controlled by glucocorticoid receptor-mediated mechanisms,
acting in concert with several other transcription factors such as Egr-1, AP2, Sp1, and MAZ [6,39,56,57].
The proximity of adrenocortical cells to the adrenal medulla guarantees high circulating glucocorticoid
levels, which cross the chromaffin cell membrane through passive diffusion. Glucocorticoid binds to
the intracytoplasmatic glucocorticoid receptor, and the receptor–hormone complex migrates to the cell
nucleus and binds to the glucocorticoid response element of the promoter region of the PNMT gene
located on chromosome 17q12, activating gene transcription [7,58,59]. This explains why the adrenal
gland is the body’s most important source of epinephrine, whereas the expression of extra-adrenal
PNMT is limited to a small number of neurons in the central nervous system and to a subset of
cardiomyocytes [6,60,61].
2.1.5. Co-Secreted Products
Chromaffin cells of the adrenal medulla synthesize a large variety of other substances, such as
neurotransmitters, enzymes, peptides, and proteins, which are also stored in chromaffin vesicles and
co-secreted along with catecholamines [62–64]. Over the past decades, the components of this vesicular
cocktail have been studied in great detail (Table 1).
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Table 1. Overview of the co-secreted products of chromaffin vesicles with description of their function in normal adrenal medulla and reported alterations in
pheochromocytoma and paraganglioma (PPGL).
Component Function in Human Adrenal Medulla Reported Alterations in PPGL
Granins
Chromogranin A–C [65–77]
Role in vesiculogenesis, vesicle protein stability, hormone storage within vesicles.
Sorting proteins in the regulated secretory pathway.
Precursor protein for several peptides; chromogranin A (vasostatin I–II, catestatin,
cateslytin, chromacin, chromofungin, pancreastatin, parastatin, WE-14, EL35),
chromogranin B (secretolytin), chromogranin C (secretoneurin, EM66, manserin).
Higher plasma levels of chromogranin A and B are reported in PPGL compared to
healthy volunteers.
Chromogranin C mRNA was overexpressed in PPGL compared to non-tumoral
chromaffin tissue.
Higher expression of chromogranin A and B in RET associated PPGL compared to
VHL associated PPGL at both the mRNA and protein levels.
Downregulation of chromogranin B and chromogranin C observed to be associated
with malignant behavior.
Secretogranins III–VII [78–87]
Secretogranin III (syn. 1B1075) not found in adrenal medulla.
Presence of secretogranin IV (syn. HISL-19), V (syn. 7B2), VI (syn. NESP55) and VII
(VGF) reported in human adrenal medulla, exact function still mainly unknown.
Proposed role of secretogranin VII (syn. VGF) in the regulation of
energy homeostasis.
More pronounced immunoreactivity of secretogranin IV in malignant PPGL
compared to benign PPGL.
Significantly higher plasma levels of secretogranin V in PPGL compared to
age-matched normal subjects.
Secretogranin VI immunoreactivity found in PPGL with no differences between
benign and malignant tumors. Variable proVGF-immunoreactive fragments are
observed in human PPGL.
Glycoproteins
Glycoprotein I–V [88–90]
Glycoprotein I, i.e., DBH, catalyzes the conversion of dopamine into
norepinephrine. Glycoprotein IV, i.e., the H+-ATP-ase subunit M45, provides the
driving force for vesicular uptake of catecholamines by VMAT.
High expression levels of glycoprotein I (DBH) are reported in PPGL.
Prohormone processing enzymes
Aminopeptidase B (Ap-B) [91] Exopeptidase involved in final conversion of proenkephalin to enkephalin. Association of Ap-B with the secretory machinery is suggested in ratpheochromocytoma (PC12) cells.
Aspartic Proteinase [92] Contributes to enkephalin precursor cleaving activity. Unknown
Carboxypeptidase E (CPE) [93,94] Role in peptide processing and sorting of prohormones.
High expression of CPE mRNA are reported. Elevated expression correlated with
tumor growth and metastasis in pheochromocytomas.
CPE promotes survival of pheochromocytoma (PC12) cells under nutrient
starvation and hypoxic conditions by upregulation of pro-survival genes possibly
by activation of the ERK1/2 pathway.
Cathepsin L [95,96] Endopeptidase involved in proteolysis of proenkephalin into (Met)enkephalin.Proprotein convertase for biosynthesis of NPY and catestatin. Unknown
Prohormone convertase 1/3
and 2 [73,78,97] Conversion of chromogranin C into secretoneurin and EM66.
PC1 and PC2 mRNA expression levels are significantly higher in benign and
malignant PPGL compared to normal adrenal medulla. mRNA expression and
protein levels of PC1 and PC2 is 3–4 times higher in benign tumors compared to
malignant tumors.
Tissue-Type Plasminogen Activator
(t-PA) [98,99]
Participation in plasmin-dependent processing of bioactive peptides including
chromogranin A and indirectly modulate chromogranin A release
(negative-feedback loop).
Marked expressions of t-PA mRNA are reported in human pheochromocytomas.
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Table 1. Cont.
Component Function in Human Adrenal Medulla Reported Alterations in PPGL
Granins
Inhibitors of endogenous proteases
Endopin 1–2 [100]
Endopin 1 inhibits trypsin-like serine proteases.
Endopin 2 inhibits papain-like cysteine proteases, including cathepsin L, as well as
the serine protease elastase.
Unknown
Transmitter peptides
Adrenomedullin [65,101–105] Increases blood flow in the adrenal gland. Increases catecholamine release. Inducessystemic vasodilation. Increases natriuresis.
High plasma levels are reported, especially in PPGL patients with high
blood pressure.
Bombesin [106–108] Modulation of stress response. Paracrine regulatory effects on growth, structureand function of the adrenal cortex.
Highly variable immunoreactivity in pheochromocytomas and paragangliomas.
An association between clinically malignant PPGL and lower expression of bombesin
is postulated.
Calcitonin Gene-Related
Peptide [109,110]
Vasodilatation, enhances aldosterone and corticosterone release by
adrenocortical cells. Slightly elevated levels are reported.
Catestatin, Cateslytin [111,112] Inhibits release of catecholamines, chromogranin A, NPY, and ATP by acting asnoncompetitive antagonist of the nicotinic receptor. Unknown
EM66 (via PACAP) [73,113,114] Derivate from chromogranin C (syn. secretogranin II). Synthesis and secretionregulated by PACAP. Paracrine regulation of steroidogenic cells in the adrenal gland. Elevated in PPGL. Higher levels of EM66 reported in benign vs. malignant PPGL.
Natriuretic peptides (ANP, BNP,
CNP) [102,115,116]
Autocrine/paracrine inhibition of catecholamine secretion via the ANF-R2 receptor
subtype. Inhibition of aldosterone production by a direct action on the adrenal
cortex both in vivo and in vitro.
Elevated in PPGL patients with high blood pressure.
Neuropeptide Y (NPY)
[65,76,101,117–122]
Increases catecholamine biosynthesis (stimulates TH gene expression) and secretion.
Potentiates catecholamine induced vasoconstriction.
Influence on tumorigenesis and stimulation of neoangiogenesis is described. High
levels of NPY mRNA have been found in benign tumors, whereas its plasma levels
are elevated in patients with malignant PPGL.
Significantly lower expression level of NPY in VHL associated PPGL compared to
other hereditary and sporadic PPGL is reported.
Neurotensin [123,124] Not detected in human adrenal medulla. Various central and peripheral effects havebeen postulated in bovine, cat and rat, e.g., hypotension, hypothermia, analgesia. Neurotensin has rarely been demonstrated in human PPGL.
Opioid peptides (enkephalins,
endorphins) [96,117,125–128]
Decrease catecholamine release via binding Gi protein coupled receptor resulting in
inhibition of Ca2+ channels
Analgesia, enhancement of immune reaction.
Enkephalin decreases norepinephrine release in human pheochromocytomas.
Different enkephalins (i.e., (Met)enkephalin, (Leu)enkephalin) are observed in
human pheochromocytomas. Expression of (Met) enkephalin and (Leu)enkephalin
is highly variable compared to normal adrenal medulla. Possible association
between malignant PPGL and lower expression of enkephalins.
PACAP [40,63,101,117,129,130]
Induces transcription and stimulates activity of TH, DBH, and PNMT Stimulates
expression and secretion of several other peptides e.g., brain natriuretic peptide,
enkephalins, EM66, and secretoneurin.
High mRNA expression of PACAP and PAC1-R in PPGL reported. Comparable
expression levels in benign and metastatic PPGL found in a relatively small series.
Secretoneurin (via PACAP) [131–133]
Derivate from chromogranin C (syn. secretogranin II). Synthesis and secretion
regulated by PACAP. Role in angiogenesis and modulation of inflammatory
response by chemoattractant effects on monocytes, eosinophils, fibroblasts, vascular
smooth muscle cells, and endothelial cells.
Unknown
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Table 1. Cont.
Component Function in Human Adrenal Medulla Reported Alterations in PPGL
Transforming Growth Factor
β [134–136]
Role in regulation of chromaffin cell proliferation and differentiation. Reduction of
TGF β has been shown to increase proliferation of chromaffin cell in vivo. Unknown
Granins
Vasostatins [137–139]
The N-terminal fragment of chromogranin A
Inhibition of endothelin-induced vasoconstriction
Antibacterial and antifungal activity.
Unknown
Anti-bacterial/anti-fungal peptides
Chromacin P, G and PG [140] Antibacterial activity against Gram positive bacteria. Unknown
Secretolytin [141] Antibacterial activity against Gram positive bacteria. Unknown
Ubifungin [142] Antifungal activity. Unknown
Other minor components
Ascorbic acid [143] Regulation of DBH activity. Unknown
Coenzyme A glutathione
disulfide [144] Vasoconstriction, modulation of AngII effects. Unknown
Ions (Ca2+, Na+, K+, Mg2+, Cl−) [145] Regulation of exocytosis. Unknown
Galanin [81,146,147] Stimulation of norepinephrine and glucocorticoid secretion.
Immunoreactivity in human PPGL.
Higher levels reported in PPGL compared to normal adrenal medulla.
Variable expression; galanin was predominantly found in noradrenergic
pheochromocytoma cells.
Induction of apoptosis in PC12 cells.
Inhibition of dopamine secretion in pheochromocytoma cells.
Nucleotides (ATP, ADP, GTP) [148] Formation of intravesicular complex with catecholamines, buffer function,decreases intravesicular osmotic pressure, neuromodulation. Unknown
Substance P [149–153] Inhibition of nicotinic acetylcholine receptor mediatedcatecholamine release. Vasodilation.
Variable immunoreactivity demonstrated in human pheochromocytomas. Elevated
plasma levels in minority of patients.
Vasoactive intestinal
polypeptide [154–156] Stimulation of catecholamine release, stimulation of steroid secretion. Few cases described of human PPGL with concomitant excessive VIP secretion.
Abbreviations: ANF-R2, atrial natriuretic factor receptor subtype 2; AngII, angiotensin II; CGA, Chromogranin A; CGB, Chromogranin B; CGC, Chromogranin C; DBH, dopamine
β-hydroxylase; HISL-19, human islet cell antigen 19; NESP55, neuroendocrine secretory protein 55; NPY, Neuropeptide Y; PACAP, pituitary adenylate cyclase-activating polypeptide;
PAC1-R, PACAP-preferring receptor; PC, Prohormone-Converting Enzymes; TH, tyrosine hydroxylase.
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Among these substances, chromogranin A and the trophic and secretion stimulating peptides
pituitary adenylate cyclase-activating polypeptide (PACAP), neuropeptide Y (NPY), and adrenomedullin
(AM) have gained the most attention because of their endocrine, paracrine, and autocrine effects,
their importance for vesiculogenesis, and their possible roles in neoplastic chromaffin cell proliferation,
differentiation, and survival, as further discussed below [62–65,101,113,129,157].
2.2. Storage and Secretion of Catecholamines
2.2.1. Storage and Vesicular Transmembrane Dynamics
In adrenomedullary chromaffin cells, catecholamines are stored in specialized vesicles.
The bidirectional vesicular–cytosolic exchange of catecholamines is a dynamic process of active
uptake into these chromaffin storage vesicles and passive leakage from vesicles into the cytosol [3].
After synthesis, dopamine and epinephrine are actively transported from the cytosol into chromaffin
storage vesicles by vesicular monoamine transporters (VMAT1 and VMAT2) [158,159]. The driving
force for this active transport is provided by an ATP-dependent vesicular membrane proton pump that
maintains a transvesicular hydrogen ion (H+) electrochemical gradient by acidifying the vesicle matrix.
Vesicular uptake for catecholamines via VMAT is accompanied by exchange of an H+ ion from the
vesical matrix towards the cytosol [62,160] (Figure 1).
2.2.2. Characteristics of Chromaffin Storage Vesicles
Chromaffin storage vesicles are highly specialized organelles of the chromaffin cells for storage
and exocytosis. These membrane-bound electron-dense organelles originate from the Golgi network
and are 150 to 350 nm in diameter. Each adrenomedullary chromaffin cell contains about 12,000 to
30,000 of these vesicles, corresponding (on average) to 13.5% of the cytoplasmic cell volume [63,65].
The adrenal medulla of some species harbors two distinct populations of chromaffin cells,
which either produce epinephrine or norepinephrine depending on the presence or the absence
of PNMT [3,11,63]. The proportion of epinephrine versus norepinephrine producing chromaffin
cells in the adrenal medulla varies between species, but the adrenergic phenotype usually
predominates [3,6,62,63,161]. This is particularly so in humans, where most chromaffin cells
appear to have mixed function [6,11,62,161,162]. Nevertheless, there are clear ultrastructural
differences between epinephrine and norepinephrine-containing vesicles when studied by electron
microscopy. Epinephrine-containing vesicles are round or elongated in shape and demonstrate
fine granular, medium-density vesicles with a characteristic narrow and uniform peripheral halo,
whereas norepinephrine-containing vesicles demonstrate a high density and homogeneous content with
a limiting membrane, which may be separated from the matrix constituents by a prominent lucent halo.
The mechanisms initiating and regulating the biogenesis of chromaffin vesicles are largely
unknown. It is believed that structural proteins of the granin family, in particular chromogranin A,
have an important role in vesiculogenesis, providing structural domains that drive chromaffin vesicle
formation in the Golgi network. Furthermore, the ability of chromogranin A to bind catecholamines is
thought to regulate stability of the vesicle by reducing osmotic pressure, thereby preventing vesicles
from bursting; it is also thought to protect catecholamines against enzymatic degradation until secretion
is warranted [27,63,65].
After the formation of chromaffin vesicles, maturation continues with catecholamine synthesis
and storage not occurring until late in vesicle formation [63]. Fully matured chromaffin vesicles remain
in the chromaffin cell until stimulation for exocytosis [63,65].
The molecular composition of chromaffin vesicles is complex. Besides catecholamines,
intravesicular contents include a diverse mixture of peptides, proteases, enzymes, and granins
(chromogranins, secretogranins) with a multiplicity of functions (Table 1). The high concentration of
regulatory and modulating peptides and proteins reflects broad endocrine, paracrine, and autocrine
functions of adrenomedullary chromaffin vesicles. The physiological processes modulated by these
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constituents not only involve the fine-tuning of catecholamine biosynthesis and secretion but also
encompass various analgesic, immunomodulatory, antimicrobial, and anti-inflammatory responses to
cell stress [62,63].
2.2.3. Secretion and Re-Uptake of Catecholamines
After exocytosis of storage vesicles and secretion of catecholamines into the bloodstream,
norepinephrine and epinephrine are removed from the circulation by neural and extra-neuronal
monoamine transporters and are inactivated by metabolizing enzymes [163]. The re-uptake mechanism
through the norepinephrine transporter (NET) by catecholamine synthesizing cells is only relevant in
sympathetic postganglionic and central nervous system neurons and provides rapid termination of the
neurotransmitter signal at the postsynaptic membrane and enables recycling of catecholamines for
re-release. NET is not only located presynaptically but also at several extraneuronal sites, including
the adrenal medulla [31,163,164]. The precise function of the NET in the adrenal gland is, however,
not entirely clear. A detailed discussion of reuptake as well as pre- and postsynaptic effects of
catecholamines is beyond the scope of the current review, and for further reading, we refer to the
literature [163,165,166].
2.3. Regulation of Adrenomedullary Activity
2.3.1. Stimulus-Dependent Exocytosis in Adrenal Chromaffin Cells
Exocytosis of chromaffin storage vesicles is a tightly controlled process. Under basal conditions,
only a few secretory vesicles are released into the circulation, resulting in a catecholamine secretion rate
in the order of nanograms per minute [117]. Toxic effects of excessive chronic catecholamine release such
as in heart failure, pulmonary edema, and malignant hypertension have been reported from incessant
circulating catecholamine concentrations of 10−6 mol/L or more, corresponding to the release of 5%
of all adrenomedullary chromaffin vesicles [167]. In acute stress situations, the amount of released
vesicles from the total adrenal gland can be temporarily greatly increased, with plasma catecholamine
concentrations reaching up to 60 times more than normal [117,167]. Well-known stimuli that activate
the exocytotic process are hypoglycaemia, hypovolemia, hypotension, hypoxemia, and severe pain or
emotional distress [3].
The rather complex mechanisms regulating chromaffin cell exocytotic machinery are executed at
neuronal and non-neuronal levels [145,167–169]. It is thought that each adrenomedullary chromaffin
cell receives its own individual neuronal and non-neuronal input [167].
At a neuronal level, adrenomedullary chromaffin cells are innervated by the cholinergic
preganglionic sympathetic fibers of the splanchnic nerve. One single chromaffin cell can receive input
by up to five synapses [170]. Acetylcholine released by these nerve endings predominantly binds
to nicotinic receptors on the chromaffin cell, resulting in membrane depolarization with subsequent
calcium influx followed by stimulation of exocytosis and catecholamine secretion. Cholinergic receptors
of the muscarinic type are also expressed on the chromaffin cell, but their contribution to catecholamine
secretion is less important. Further enhancement of the stimulation–secretion coupling is provided by
propagation of the secretion signal via gap junctions between chromaffin cells formed by connexins,
which are specific proteins involved in cell-to-cell communication. This intercellular communication
can be upregulated in stressful conditions [170]. Besides acetylcholine, splanchnic nerve terminals
also contain PACAP as a neurotransmitter. This neuropeptide is not only stored in chromaffin vesicles
and co-secreted with catecholamines but also acts as an important neurotransmitter at the splanchnic
medullary synapse, where it activates the PACAP-preferring receptor (PAC1-R) on the postsynaptic
membrane of the chromaffin cell. Laboratory experiments have shown that PACAP is only released at
high frequencies of nerve stimulation, which is the firing rate occurring in stress conditions. In contrast
to the acetylcholine evoked catecholamine secretion, adrenomedullary stimulation by PACAP is
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not susceptible to desensitization, which ensures robust catecholamine release under conditions of
continuous stress (Figure 2) [40,130].
Figure 2. Schematic overview of the stimulation–secretion coupling in the adrenomedullary
chromaffin cell with the multiple functionally definable stages and the different secretory pathways.
Abbreviations: ER: endoplasmic reticulum; Ach: acetylcholine; VAMP: vesicle-associated membrane
protein; SNAP: synaptosomal-associated protein; NSF: N-ethylmaleimide Soluble Factor proteins;
CADPS: Ca2+ dependent secretion activator; CALM: calmodulin; PACAP: pituitary adenylate
cyclase-activating polypeptide; PAC1 receptor: PACAP-preferring receptor; GR: glucocorticoid receptor.
Non-neuronal regulation of exocytosis occurs predominantly through autocrine or paracrine
routes. As a result, cellular catecholamine secretion is partially under the influence of the exocytotic
activity of neighboring chromaffin cells [167]. Furthermore, both lipopolysaccharide and cytokine
receptors were recently demonstrated on chromaffin cells, pointing towards a role of the adrenal
medulla in the complex regulation of the inflammatory stress response [40].
In general, the exocytotic secretion of vesicular contents of adrenomedullary chromaffin cells can be
achieved via regulated and constitutive secretory pathways. The regulated secretory pathway provides
the principle mechanism responsible for controlled release of catecholamines and is calcium-dependent
and responsive to both neuronal and non-neuronal input. In contrast, the constitutive secretory
pathway, which is calcium-independent, is mainly unresponsive to neuronal and non-neuronal input.
The principal function of the constitutive secretory pathway is thought to be the transport of proteins
and macromolecules to the cell surface for purposes of membrane maintenance and support of the
extracellular matrix. In addition, this pathway may also contribute to basal release of catecholamines
(Figure 2) [145,169].
2.3.2. Neuronal Regulation of the Calcium-Dependent Catecholamine Secretory Pathway
In recent years, considerable progress has been made in unravelling the complex molecular
background and the functional elements of the highly regulated exocytotic machinery in
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adrenomedullary chromaffin cells (Figure 2) [145,171,172]. Release of acetylcholine by the splanchnic
nerve activates the nicotinic receptor on chromaffin cells, resulting in opening of the ionophoric part
of the receptor protein, thereby allowing the entry of extracellular sodium (Na+) and calcium (Ca2+).
This generates a small membrane depolarization, resulting in the opening of voltage dependent Na+
channels. The subsequent Na+ influx results in a large membrane depolarization, which opens various
types of voltage dependent Ca2+ channels [167].
The distribution of the different calcium channel subtypes is species specific. The P/Q-type calcium
channel predominates in human adrenomedullary chromaffin cells [167,171,172]. As a consequence of
elevated intracellular Ca2+ concentrations, the exocytotic machinery and the regulatory components
for vesicular exocytosis are activated, which occurs through a pathway consisting of secretory vesicle
recruitment, docking, priming, and fusion with the plasma membrane. Priming is the process in which
secretory vesicles become fusion competent [167,172]. First, Ca2+ influx leads to dismantling of the
cortical actin cytoskeleton of the chromaffin cell, a dynamic network of numerous cytoplasmic proteins
located on the inner face of the chromaffin cell membrane [173]. Although this can be activated without
Ca2+, this is mainly an ATP and a Ca2+ dependent step, as are recruitment, tethering, and docking of
the vesicles.
Fusion, release, and retrieval of vesicles can be triggered by Ca2+ in the absence of ATP [145,174].
Various soluble and membrane-bound proteins are involved in the complex protein–protein interactions
underlying membrane trafficking and fusion. Key components of this process are N-ethylmaleimide
soluble factor proteins (soluble cytosolic NSF), soluble NSF attachment proteins (SNAPs), and soluble
NSF attachment receptor proteins (SNAREs). The vesicle-associated membrane protein (VAMP or
synaptobrevin) and the calcium binding protein synaptotagmin are SNAREs located at the secretory
vesicle membrane. The synaptosomal-associated protein 25 (SNAP-25) and syntaxin are SNAREs
acting on the chromaffin cell plasma membrane [145,167,172]. The complex formed by chromaffin
vesicle SNAREs (VAMP, synaptotagmin), the chromaffin cell membrane SNAREs (syntaxin, SNAP-25),
and the cytosolic proteins (NSF) is thought to provide the primary molecular machinery responsible
for the docking and the fusion of synaptic vesicles at the chromaffin cell plasma membrane
(Figure 2) [174]. Furthermore, it is believed that NSF and SNAPs have multiple sites of actions
on SNARE proteins. Besides pre-docking actions and their function as molecular chaperones in SNARE
priming, they also act on SNAREs post-fusion to facilitate vesicle retrieval and allow recycling of empty
vesicles [145,167,172,174].
Apart from NSF, SNAPs, and SNAREs, several other proteins are involved in calcium
triggered exocytosis. Proposed candidates are the stabilizing protein Munc18-1, the calcium
transducer calmodulin (CALM), the Ca2+ dependent secretion activator (CAPS), rabphilin,
and annexins [169,172,174]. Rabphilin3A is a small GTP-ase, which acts as a molecular switch,
thereby determining the sensitivity of secretory vesicles for docking and fusion. Overexpression of
rabphilin3A has been found to inhibit exocytosis in adrenomedullary chromaffin cells and probably
protects against spontaneous exocytosis under basal conditions [175]. Annexins have the ability to
form cross-links between secretory vesicles and the plasma membrane by a functional interplay with
SNAREs during exocytosis [145,169,176–178].
2.3.3. Non-Neuronal Regulation of Catecholamine Secretion
Along with catecholamines, the adrenal medulla synthesizes and releases numerous
enzymes, peptides, and proteins that exert various trophic and neurotransmitter activities,
which provide fine-tuning of catecholamine synthesis and secretion in an autocrine and
a paracrine manner [62–65,101,111,113,117,118,129,157] (Table 1). We discuss here in more detail
neuropeptide Y (NPY), adrenomedullin (AM), PACAP, and the secretion-inhibiting peptide
catestatin [101,111,117,118,129]. These peptides modulate chromaffin cell function through a variety of
membrane receptors, the vast majority of which belong to the family of G protein-coupled receptors
(GPCRs) [117].
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Neuropeptide Y is a 36-amino acid neuropeptide, which is widely and abundantly distributed in
the brain and the sympathetic nervous system, including the human adrenal medulla. Several NPY
receptors (i.e., Y1, Y2, Y4, and Y5) are expressed in the adrenal gland, indicating that NPY exerts local
autocrine effects. It has been shown that NPY is able to stimulate catecholamine secretion by inducing
TH expression and increasing intracellular calcium [63,101,117,118,129,179].
Adrenomedullin (AM) is a 52-amino acid peptide originally isolated from a human
pheochromocytoma and also is present at high concentrations in the normal adrenal
medulla [101,117,129]. AM demonstrates autocrine and paracrine effects through binding to the
adrenomedullin receptor (ADMR), the receptor dog cDNA (RDC1), and the calcitonin receptor-like
receptor (CRLR), which results in augmentation of the adrenal blood flow and stimulation of
catecholamine release. In addition, the endocrine effects of AM include systemic vasodilatation
and stimulation of natriuresis [63,101,117,129].
As previously mentioned, PACAP not only acts as a neurotransmitter released by the splanchnic
nerve but is also co-secreted with catecholamines, exerting its effects by binding to the PACAP-preferring
receptor (PAC1-R) and VIP/PACAP receptors (VPAC1-R and VPAC2-R), the former representing the
predominant receptor in chromaffin cells (Figure 2) [101,117,129]. PACAP, a neuropeptide of 27 or
38 amino acids, enhances catecholamine secretion by induction of transcription as well as stimulating
the activity of the biosynthetic enzymes TH, DBH, and PNMT [101]. In normal adrenal medullary
chromaffin cells, PACAP also stimulates the expression and the secretion of several other peptides,
such as brain natriuretic peptide, enkephalins, EM66, and secretoneurin, which in turn exert their own
individual autocrine/paracrine effects on catecholamine secretion [40,63,101,117,129,130].
Catestatin is a biologically active peptide fragment derived from proteolytic chromogranin
A cleavage [63]. Catestatin acts mainly as a noncompetitive nicotinic cholinergic antagonist,
thus providing a strong negative feedback inhibition of catecholamine secretion [111,112].
3. Pheochromocytoma and Paraganglioma
From a genetic perspective, pheochromocytomas and paragangliomas (PPGL) have one of the
richest hereditary backgrounds among all neoplasms. At least 35—perhaps up to 40%—of all PPGL
harbor a germline pathogenic variant in one of the several susceptibility genes [180–184]. Initial gene
expression profiling studies by Dahia et al. in 2005 [185] revealed two cluster groups, designated
cluster 1 and cluster 2, that reflected respective activation of pseudohypoxia and kinase signaling
pathways. Those different gene expression signatures matched closely to those reported in an earlier
study for norepinephrine- versus epinephrine-producing sporadic tumors and tumors from patients
with von-Hippel Lindau (VHL) syndrome and multiple endocrine neoplasia type 2 (MEN2) [186].
The molecular characterization from The Cancer Genome Atlas (TCGA) project has more recently
provided a sophisticated molecular taxonomy of PPGL, which divides these neuroendocrine tumors
into groups with similar pathogenesis and molecular biology and provides an up-to-date framework
(Figure 3) [187–189]. The recent identification of newly recognized somatic mutations in the driver
genes, Cold shock domain-containing E1 (CSDE1) and Mastermind-like transcriptional coactivator 3 (MAML3),
could add a third cluster—i.e., the Wnt altered group [187]—to the original classification of Dahia et al.
of 2005 [185]. This cluster 3 is associated with an abnormal activation of the Wnt-signaling pathway.
Cluster 1, the pseudohypoxia group, can be subdivided into a tricarboxylic acid (TCA) cycle-
and a VHL/EPAS1 related group. The TCA cycle-related subgroup consists of germline pathogenic
variants in genes encoding fumarate hydratase (FH) or one of the succinate dehydrogenase (SDH)
subunits A, B, C, D, or the complex assembly factor 2 (AF2). Germline pathogenic variants in Malate
Dehydrogenase 2 (MDH2) and somatic mutations in Isocitrate Dehydrogenase type 2 (IDH2) genes also
can be categorized in this subgroup [190,191]. The VHL/EPAS1-related subgroup consists of germline
and somatic pathogenic variants in the genes VHL and EPAS1 [encoding the hypoxia inducible factor
2α (HIF2α) protein] [192]. In addition, it was proposed that mutations in genes encoding prolyl
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hydroxylase 1 (PHD1, also known as egl nine homolog 2; EGLN2) and iron regulatory protein 1 (IRP1)
should also be considered as members of this subgroup [193].
Figure 3. The Pseudohypoxia group (cluster I) divided into two subgroups: tricarboxylic acid (TCA)
cycle related, containing germline pathogenic variants in succinate dehydrogenase subunits SDHA,
SDHB, SDHC, and SDHD as well as SDHAF2 (SDHx), assembly factor for the succinate dehydrogenase
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complex, and FH, a second enzyme in the tricarboxylic acid (TCA) cycle. The second subgroup:
VHL/EPAS1—related with somatic and germline pathogenic variants. Pathogenic variants in three
additional genes encoding for malate dehydrogenase 2 (MDH2), prolyl hydroxylase 1 (PHD1, also known
as egl nine homolog 2; EGLN2), and iron regulatory protein 1 (IRP1) were not included previously in the
molecular classification by TCGA but were recently discovered. Based on their signaling pathways, it is
believed that these new genes should be included as part of the cluster I pseudohypoxia group because
MDH2 is part of to the TCA cycle and both PDH1 and IRP1 belong to the VHL/EPAS1 related subgroup.
Cluster I is characterized by the expression of genes involved in the “hypoxic response”, resulting in a
“pseudo-hypoxic” phenotype with uncontrolled expression of HIF1α regulated genes such as VEGF.
HIF1α regulates the transcription of genes associated with tumorigenesis and angiogenesis. Wnt altered
signaling group (cluster III) consists of newly recognized somatic mutations in CSDE1 as well as somatic
gene fusions affecting MAML3. This group exclusively consists of somatic mutations that activate the
Wnt pathway, which is not activated under normal conditions. Wnt signaling and therefore increased
expression of β-catenin is associated with a poorer prognosis and a higher metastatic potential of
tumors. There is still much unknown about this group. Kinase signaling group (Cluster II) consists of
germline or somatic pathogenic variants in the driver genes RET, NF1, TMEM127, MAX, and HRAS.
This cluster is characterized by an increased activation of the MAP kinase and the P13K/AKT pathways,
which results in an increased expression of genes involved in protein synthesis, kinase signaling,
endocytosis, and preservation of differentiated/mature chromaffin cell catecholamine biosynthetic
machinery. MAX mutated tumors are an exception, since they show an intermediate catecholamine
biochemical phenotype with detectable expression of PNMT and some production of epinephrine.
MAX is a distinct sub-cluster of the kinase signaling group and was recently proposed to be possibly
redivided in a new group, the cortical admixture group [187–189,193].
Cluster 2 related mutations are associated with abnormal kinase signaling pathways and include
germline or somatic pathogenic variants in genes encoding for rearranged-during-transfection (RET),
neurofibromin (NF1), transmembrane protein 127 (TMEM127), MYC-associated factor X (MAX),
and Harvey rat sarcoma proto-oncogene (H-RAS) [193,194].
Each of these clusters is associated with unique downstream signaling pathways, which correspond
to certain clinical features and offer potential targets for future diagnostic, therapeutic, and prognostic
purposes (Figure 3).
The hallmark of pheochromocytomas and sympathetic paragangliomas is their ability to
secrete catecholamines in an uncontrolled fashion compared to normal adrenomedullary chromaffin
cells. Unlike normal adrenomedullary chromaffin cells, chromaffin tumor cells are not innervated,
and catecholamine secretion is therefore not stimulated by the previously described neuronal
stimuli [195]. Theoretically, and as discussed below, the hypersecretion of catecholamines could
be explained by various perturbations of the molecular machinery involved in their biosynthesis,
secretion, and metabolism.
3.1. Increased Biosynthesis of Catecholamines
The most obvious explanation for the hypersecretion of catecholamines by pheochromocytomas
is the increased number of cells able to produce and secrete catecholamines. There are limited
data on the tissue concentration of catecholamines in normal adrenal medulla as compared with
pheochromocytoma, demonstrating either no difference or a higher content of epinephrine in the
latter [88,195]. At the cellular level, there is evidence of an upregulation of expression and activity
of the biosynthetic enzymes. In particular, Jarrot et al. [89] described in 1977 that the activity of
TH, AADC, and DBH was enhanced in human pheochromocytoma compared to normal human
adrenal medulla tissue specimens. These early observations were subsequently supported by several
immunohistochemical studies [196–201].
Isobe et al. demonstrated that pheochromocytoma cells contained increased levels of mRNA
encoding TH, AADC, and DBH compared to normal adrenal medulla [88]. They also found
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a strong positive correlation between TH mRNA concentration and total catecholamine content
in pheochromocytomas that was absent in normal adrenal medulla tissue. Moreover, they found lower
concentrations of PNMT mRNA in pheochromocytoma compared to normal adrenal medulla [88],
which might be explained, in part, by lower concentrations of cortisol reaching tumor tissues [88,202].
Of interest, Kimura et al. [196] demonstrated that PNMT immunoreactivity was limited to the mixed
epinephrine and norepinephrine producing pheochromocytomas, and tumor cells with PNMT tended
to be located close to the adrenal cortex.
All above referenced studies involving comparisons of pheochromocytoma tissue with normal
adrenal medulla must be interpreted cautiously since it is difficult to isolate normal adrenal
medullary from cortical tissue and thereby establish true differences between normal and tumor
cells [203]. What is clear is that catecholamine contents of pheochromocytoma or paraganglioma tumor
tissue are highly variable, both in terms of total amounts and relative content of norepinephrine and
epinephrine [195,199,204]. Most tumors produce relatively low amounts of dopamine, but there
are exceptions, usually isolated paragangliomas presumably lacking significant expression of
DBH [205–207].
3.1.1. Relationship between Genotype and Catecholamine Biochemical Phenotype
Mutation-dependent differentiation of the chromaffin progenitor cells influences the expression
of the biosynthetic enzymes, which leads to distinct phenotypic features of the tumors [206].
Three biochemical phenotypes can be distinguished, i.e., noradrenergic, adrenergic, and dopaminergic,
based on the main catecholamines that are produced. Typical pheochromocytomas produce both
norepinephrine and epinephrine in variable proportions. A small subset of PPGL is biochemically
silent, and almost all of these are paragangliomas [208,209].
The two gene expression clusters (cluster 1 and 2) described earlier are not only characterized by
distinct patterns of gene activation but also distinct catecholamine biochemical phenotypes [186,207,210].
Cluster 2 tumors due to somatic and/or germline NF1, RET, TMEM127, MAX, and HRAS pathogenic
variants, which are characterized by activated kinase and protein translation signaling pathways,
almost always originate in the adrenals and produce epinephrine due to expression of PNMT. They have
more mature catecholamine secretory pathways and phenotypic features [186,207,210] and also tend
to develop later in life than tumors due to cluster 1 mutations.
In contrast, cluster 1 tumors with the pseudohypoxic phenotype due to germline pathogenic
variants of VHL, SDHx, FH, and somatic mutations of EPAS1 (HIF2α) occur with variable frequencies
at extra-adrenal or adrenal locations and show negligible epinephrine production due to near absent
expression of PNMT [186,187,207,210]. This is also independent of their adrenal or extra-adrenal
locations due to hypermethylation of the PNMT promoter [211]. The underlying pseudohypoxic
phenotype of cluster 1 tumors is due to HIF stabilization, and it appears that it is the stabilization
of HIF2α that is more important than that of HIF1α for the distinct phenotypic features of cluster
1 compared to cluster 2 chromaffin cell tumors [186,212–215]. Indeed, HIF2α was identified in 2004 as
a key differentially expressed gene, which is more highly expressed in noradrenergic tumors compared to
adrenergic tumors, where its expression is essentially absent [186]. Mechanistic studies by Qin et al. [215]
showed that expression and the stabilization of HIF2α in chromaffin cells that normally expressed
PNMT and produced epinephrine resulted in complete suppression of steroid-induced induction of
PNMT. Since HIF2α is expressed transiently in chromaffin progenitors during embryogenesis [216–218],
it is possible that HIF2α stabilization may promote a noradrenergic rather than an adrenergic phenotype.
This concept is supported by findings that transgenic mice with mutations that stabilize HIF2α are
characterized by adrenals that express less PNMT and produce more norepinephrine than epinephrine
compared to adrenals of wild type mice [219].
Thus, it seems that cluster 1 adrenal tumors arise from chromaffin progenitors in which both
transcriptional expression of HIF2α and stabilization of the translated HIF2α protein blocks the effects
of steroids produced locally by cortical cells, explaining why these tumors in the end do not produce
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epinephrine. Such influences occurring during embryogenesis could also be responsible for the younger
age of presentation of patients with cluster 1 compared to cluster 2 tumors as well as their propensity
for a multifocal presentation [211].
The effect of HIF2α to block steroid induced expression of PNMT and other genes is suggested
to involve a mechanism involving the MYC/MAX complex and MYC-mediated control of gene
transcription [215]. A role of MAX is indicated by the demonstration that, in rat PC12 pheochromocytoma
cells, which lack a functional MAX gene, re-expression of MAX facilitates return of steroid-induced
PNMT expression. In contrast, silencing MAX in pheochromocytoma cells that express PNMT results
in attenuated steroid-induced PNMT [215]. This provides a potential point of intersection for almost
all upstream tumor susceptibility genes and also explains the catecholamine biochemical phenotype
of MAX-mutated pheochromocytomas, which express some PNMT and produce some epinephrine,
though in amounts that lie in between cluster 1 and cluster 2 tumors [207,220].
3.1.2. Relationship between Genotype and Catecholamine Secretory Pathways
The two distinct genetic clusters seem to be not only associated with differences in biochemical
profile but also with variations in secretory processes. For example, data derived from microarrays and
proteomics have shown reduced expression of various components of the regulated secretory pathway
(e.g., SNAP25, syntaxin, rabphilin 3A, annexin) in VHL-related pheochromocytomas compared to
RET-related pheochromocytomas [169]. In addition, the rate constant for baseline catecholamine
secretion was found to be 20-fold higher in VHL- than in RET-related pheochromocytoma. Moreover,
only in RET-mutated tumors catecholamine, secretion was shown to be responsive to glucagon.
These observations suggest that catecholamine secretion in VHL-associated pheochromocytomas
exhibits more constitutive-like continuous secretory characteristics, whereas in RET-associated
pheochromocytomas, secretion still is constrained by expression of many components of the regulated
secretory pathway. Thus, differences in the molecular machinery underlying catecholamine exocytosis
may explain the more paroxysmal nature of symptoms and signs in patients with MEN2 as compared to
those with the VHL syndrome. In addition, it was demonstrated that the expression of VMAT1 mRNA
was significantly higher in pheochromocytomas from VHL compared to MEN2 patients [164,189].
In addition, higher levels of VMAT1 correlated with lower tumor tissue contents of catecholamines
and lower numbers of catecholamine containing vesicles, which likely reflects the higher turnover of
catecholamines in noradrenergic VHL-related compared to adrenergic pheochromocytomas [164].
3.2. Alterations in Chromaffin Cell Pathways Associated with Metastatic Pheochromocytoma
and Paraganglioma
3.2.1. Clinical Features and Risk Factors
The majority of PPGLs are characterized by a benign clinical course. In 10–15% of cases, however,
metastases are present at diagnosis or will develop during follow-up. The most common metastatic sites
for chromaffin cell tumors are local lymph nodes, bone, liver, and lung [221]. At the moment, there are
no discriminative histopathological features by which the biological behavior of a pheochromocytoma
or a paraganglioma can be assessed or predicted reliably [222–225]. Therefore, the most recent WHO
Classification of Endocrine Organs states that all chromaffin cell tumors are considered to have
metastatic potential for which long-term follow-up of patients is required, even after successful
resection of a pheochromocytoma or a paraganglioma [221].
Several clinical risk factors have been identified that confer an increased risk for development of
metastatic disease. Large size (in general > 5 cm) and extra-adrenal location of the primary tumor are
associated with metastatic disease [226–230]. Although representing about 20% of the chromaffin cell
tumors, sympathetic paragangliomas are the primary source for about 60% of cases with metastatic
PPGL [229].
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Germline pathogenic variants of the SDHB gene are present in a relatively high frequency of 8–10%
in patients with a PPGL [184]. Large cohort studies targeted at the genotype–phenotype relationship
have shown that, in particular carriers of an SDHB germline, pathogenic variants have an increased
risk of metastatic PPGL [184,230–232]. Typical SDHB related PPGLs occur at a younger age and arise
more frequently in extra-adrenal locations [233]. A possible increased predisposition to metastatic
disease has been suggested for rare germline pathogenic variants in FH [234], SLC25A11 [235], SDHA,
and TMEM127 [236], although the number of cases is quite low, making the association difficult
to confirm.
In addition to size and location of the PPGL and the presence of certain germline mutations,
the risk of metastatic disease is also increased in association with certain alterations in the biochemical
profile [237]. In particular, plasma concentrations of dopamine and its metabolite 3-methoxytyramine
are significantly higher in patients with metastatic PPGL compared to those with non-metastatic
disease [237,238]. Most patients with metastatic PPGLs demonstrate a noradrenergic profile with
elevated plasma levels of both norepinephrine and normetanephrine, with concomitant lack of or
negligible relative increases in plasma concentrations of epinephrine and metanephrine compared to
subjects without metastatic disease [237,239]. In a relatively large series of patients with metastatic
PPGL, only a minority (11%) of patients had an adrenergic phenotype. Of note, none of these patients
had a SDHB-related pheochromocytoma or paraganglioma [240]. The biochemical profile has also
been linked to prognosis, as it was shown that patients with elevated plasma levels of dopamine and
norepinephrine had a faster progression of their disease [239].
3.2.2. Molecular Alterations in SDHx-Related PPGL and Their Effect on Catecholamine Biosynthesis
The SDH complex is a hetero-tetrameric mitochondrial enzyme that consists of two catalytic
subunits (SDHA and SDHB) and two membrane-anchoring subunits (SDHC and SDHD). SDH catalyzes
the oxidation of succinate to fumarate in the TCA cycle and transfers electrons to the ubiquinone
(coenzyme Q) pool in the respiratory chain. SDH assembly factor (SDHAF) is required for the flavination
of SDHA, an essential step in formation of the SDH complex.
SDH deficiency leads to the accumulation of succinate, which has structural similarity to
2-ketoglutarate. Succinate is therefore able to act as a competitive inhibitor of 2-ketogluarate-dependent
dioxygenases, which include prolyl hydroxylase domain proteins (PHDs), ten-eleven translocation
(TET) enzymes, and jumonji-domain histone demethylases (JmjC) demethylases [241,242]. This results
in hypermethylation of CpG (cytosine preceding guanine) islands, regions within the genome that are
common in promoter sites rich in CpG dinucleotides. Succinate is a typical example of an oncometabolite,
a metabolite that abnormally accumulates in cancer cells as a result of a defective gene encoding the
corresponding enzyme, thereby modifying signaling pathways and epigenetic regulation mechanisms.
In the study by Letouzé et al. [211], the level of hypermethylation was significantly higher in SDHB
compared to other SDHx mutated tumors. Of interest, it was shown that succinate:fumarate ratios were
higher in tumor tissue derived from patients with a SDHB pathogenic variant as compared from those
with a SDHC/D pathogenic variant [243]. This suggests that functional activity of the SDH complex
is most disrupted in the case of mutations of the SDHB subunit, resulting in higher intracellular
concentrations of oncometabolites and a concurrent higher metastatic risk.
PHDs are involved in the inactivation of the HIF, a heterodimer that consists of two subunits, one α
subunit and one β subunit. There are two different α-subunits (HIF1α and HIF2α) and two different β
subunits (HIF1 β and aryl hydrocarbon receptor nuclear translocator ARNT2). The β subunits are
constitutively expressed, whereas HIF1α and HIF2α are inactivated in the presence of oxygen through
hydroxylation by PHDs and subsequent degradation by the VHL–ubiquitination complex (pVHL).
The hydroxylation reaction performed by the PHDs requires oxygen and α-ketoglutarate as substrates
as well as iron and ascorbate as cofactors [244].
Thus, PHD is inactive in the presence of hypoxia, resulting in stabilization of HIFα. The unmodified
HIFα molecule translocates to the nucleus, where it forms a transcriptionally active heterodimer
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together with a HIFβ subunit, which is able to stimulate various target genes involved in angiogenesis,
energy metabolism, and cell survival.
The epigenetic modifications are thought to play an important role in tumorigenesis by deregulating
gene expression of key genes. Methylome analysis of a large PPGL cohort demonstrated a clear
hypermethylator phenotype in the SDHx-related tumors [211].
Besides the PNMT gene, three other genes involved in the catecholamine pathway were also
found to be hypermethylated, i.e., DRD2, NPY, and SLC6A2 [211]. Transcription of DRD2 results in the
synthesis of the D2-dopamine receptor, and the SLC6A2 gene or solute carrier family 6, member 2 gene
encodes the norepinephrine transporter (NET) responsible for reuptake of norepinephrine into
presynaptic nerve terminals.
3.2.3. Relationship between Other Components of the Exocytotic Machinery and Metastatic Disease
The co-secreted neuropeptides neuropeptide Y, adrenomedullin, and PACAP are overexpressed
in pheochromocytomas and stimulate catecholamine release [129]. These neuropeptides have also
been implicated in influencing cell survival and tumor growth of PPGLs (Table 1) [119,120,129].
High expression levels of the adrenomedullin receptor RDC1 were demonstrated in a small series
of metastatic PPGL. Overexpression of the adrenomedullin receptor RDC1 has been described in
several cancers and has been found to be associated with invasiveness, survival, proliferation, and
neo-angiogenesis [129]. These observations suggest a pathophysiological role of the adrenomedullin
receptor RDC1 in metastatic PPGL.
Recently, overexpression of LAT-1, and to a lesser extent of LAT-2, has been demonstrated in
pheochromocytoma. Moreover, LAT-1 overexpression was strongly correlated with higher levels of
urinary catecholamine excretion. It seems plausible that this enhanced expression of LAT is required to
ensure a sufficient supply of tyrosine as substrate for the increased catecholamine synthesis. Of interest,
LAT-1 expression has been described as a poor prognostic marker in various malignancies, including
lung, pancreas, breast, and hepatocellular cancer [245]. It is currently unknown whether LAT expression
has any prognostic value in PPGL [246–249].
Connexins (Cx) are the specialized proteins of gap junctions, and these structures play an
important role in cell proliferation and differentiation as well as in carcinogenesis. The connexion
family consists of 21 different proteins, and it has been demonstrated that the expression pattern of
connexins in pheochromocytomas is different from normal adrenal medulla tissue [170,250]. In addition,
the expression of Cx50 was lower in metastatic as compared to benign pheochromocytomas [250].
However, data on the association between connexion expression pattern and biological behavior of
pheochromocytomas are very limited.
In summary, our understanding of the intracellular molecular intricacies associated with metastatic
PPGL has greatly improved in recent years. Although elucidation of these pathways is still incomplete,
research of the genome–metabolome–phenotype relationship has already generated exciting and
clinically important information of these rare neuro-endocrine tumors.
4. Conclusions and Future Perspectives
In conclusion, our increased knowledge of catecholamine synthesis, secretion, and regulation
has improved our understanding of chromaffin cell tumorigenesis. Disregulation of these pathways
is evident in pheochromocytomas and paragangliomas and varies between the different genomic
backgrounds of the tumors. For example, the differences in PNMT, VMAT, RDC1, and LAT1 expression
may signify a difference in cellular dedifferentiation, making certain tumors more aggressive.
In addition, substances such as neuropeptide Y, PACAP, EM66, bombesin, and connexins might
be differentially expressed by benign and metatstatic PPGL. These potential prognostic biomarkers
will need to be examined in larger and more broad cohorts of PPGLs and in prospective studies to
determine their true potential utility as prognostic markers. Moreover, further studies of chromaffin
cell products with an unknown role in PPGL (Table 1) might also reveal clinically useful information.
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Future research will continue to provide novel and relevant information that will enhance our
current knowledge with respect to both the physiology and the pathophysiology of the chromaffin cell.
To this end, an integrative and translational approach is required by combining clinical information
with (epi)genomics, transcriptomics, and metabolomics. Such new information could, for example,
elucidate the precise relationship between the net effect of the mixture of substances that are co-secreted
with catecholamines and the clinical picture. In addition, it would allow better discrimination between
benign and potentially metastatic PPGL at the time of initial diagnosis. Moreover, improved insight into
the molecular pathways that drive the transformation of the normal chromaffin cell into the malignant
chromaffin cell will also offer novel targets for treatment that hopefully will provide a definitive cure
for these rare metastatic neuroendocrine tumors in the future.
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